Zacks Research lowered shares of ARS Pharmaceuticals (NASDAQ:SPRY – Free Report) from a hold rating to a strong sell rating in a report published on Tuesday,Zacks.com reports. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of ARS Pharmaceuticals in a research report on Wednesday, January 21st. Based on data from MarketBeat.com, ARS Pharmaceuticals presently has an average rating of “Hold” and a consensus target price of $33.00. Get ARS Pharmaceuticals alerts:Read Our Latest Research Report on SPRYARS Pharmaceuticals Trading Up 0.7%Shares of SPRY traded up $0.07 during trading hours on Tuesday, hitting $10.13. Featured StoriesReceive News & Ratings for ARS Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ARS Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.